LIPOSOME CO. HALTS MAITEC LIPOSOMAL GENTAMICIN DEVELOPMENT
LIPOSOME CO. HALTS MAITEC LIPOSOMAL GENTAMICIN DEVELOPMENT worldwide "to focus the company's resources on its other products," the Princeton, N.J. liposome encapsulation company reported Feb. 23. The Liposome Company previously had announced at the Wheat First/Butcher & Singer health care conference Oct. 26 that Phase III trials of its liposomal gentamicin for Mycobacterium avium intracellulare in AIDS patients would begin in "several months" ("The Pink Sheet" Nov. 8, 1993, T&G-5). At the time, a Phase IIb trial was under way in the U.S. and a Phase III trial was ongoing in Europe. All developmental efforts have now been "suspended."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth